With Clarient Purchase, NeoGenomics Hoping to Offer Most Comprehensive Cancer Genetics Test Menu | GenomeWeb

NEW YORK (GenomeWeb) – NeoGenomics aspires to become "America's premier cancer testing laboratory."

While searching for a company that could move NeoGenomics closer to achieving this goal, GE Healthcare Life Sciences' unit Clarient rose to the top of the list, CEO Douglas VanOort told investors and analysts during a call last week. After a year of negotiations with GE Healthcare, the Fort Myers, Florida-headquartered cancer reference lab last week announced it was buying Clarient in a cash and stock deal worth approximately $275 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.